Healthcare >> CEO Interviews >> November 1, 2002
PHILIP TABBINER, President and Chief Executive Officer of
aaiPharma Inc., oversees all aspects of aaiPharma's business
operations including the pharmaceutical products division; the
research, licensing and product development division; AAI
International (the contract research services business); and all
corporate administrative functions. Dr. Tabbiner was named a
member of the Board of Directors on July 1, 2002. He joined
aaiPharma in 2000 as President of the Pharmaceuticals Division,
formerly known as NeoSan Pharmaceuticals. Dr. Tabbiner is a
veteran of the pharmaceutical and healthcare industry whose
career has included executive positions at Bayer Corporation,
Chiron Corporation and DuPont Merck Pharmaceuticals. Dr. Tabbiner
spent nearly 20 years with DuPont Merck with responsibilities
spanning from overseeing the Canadian operations of the
pharmaceuticals business, to running the original generics
business, to directing North American marketing for the
pharmaceuticals business, to leading the worldwide sales and
marketing for the Radiopharmaceuticals Division. After leaving
DuPont Merck, Dr. Tabbiner joined Chiron as President of
International and, when Bayer acquired Chiron, he moved on to
Bayer Diagnostics to lead the business development, strategic
planning and marketing aspects of the business. Dr. Tabbiner has
his doctorate in Business Administration, an MBA in Strategic
Management and a Bachelor's Degree in Economics. He has held
numerous positions in industry organizations and business
councils. Profile
Dr. Tabbiner: aaiPharma is a unique science-based specialty
pharmaceutical company. We operate in three business areas. A
services business,
